| Name | Title | Contact Details |
|---|---|---|
Jacqui Boire |
Director, Technology Strategy and Planning | Profile |
Were reimagining how technology can solve #stroke`s unmet needs, enabling providers with the ability to raise the standard of care for patients.
XTuit Pharmaceuticals, Inc. is a biopharmaceutical company developing novel microenvironment-activated therapeutics targeting key mechanisms resulting in hypoxia, decreased drug uptake, drug resistance, and decreased immune response. The Company’s proprietary drug development pipeline and integrated, sophisticated clinical biomarker platform will be used for accelerated clinical development across selected cancers and fibrotic disorders. XTuit’s compounds act through pleiotropic mechanisms to inhibit extracellular matrix synthesis and stabilization, and to silence activated stromal cells, including cancer-associated fibroblasts and stellate cells. As a result, XTuit compounds alleviate hypoxia and enable enhanced drug uptake through solid stress reduction. Moreover, the drugs have been shown to down-regulate stroma-induced tumor and inflammation signaling pathways to overcome treatment resistance. XTuit’s first two lead series are being developed for early clinical proof-of-concept in liver diseases and cancer.
PAR Pharmaceuticals is a Woodcliff Lake, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BrainsWay is an Israeli company with international operations that is engaged in the development of a medical device that uses H-coil for deep transcranial magnetic stimulation as a noninvasive treatment for depression.
Graceway Pharmaceuticals is a Bristol, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.